Table 1. Participant demographics.
| Variables | Fasting study | Fed study | |||||
|---|---|---|---|---|---|---|---|
| Sequence A RT† (n = 30) | Sequence B TR† (n = 30) | Total (n = 60) | Sequence A RT† (n = 30) | Sequence B TR† (n = 30) | Total (n = 60) | ||
| Age (yr) | |||||||
| Mean ± SD | 24.5 ± 3.9 | 23.4 ± 2.7 | 24.0 ± 3.4 | 25.3 ± 4.1 | 24.2 ± 4.2 | 24.8 ± 4.2 | |
| Range | 19.0–35.0 | 19.0–31.0 | 19.0–35.0 | 19.0–34.0 | 19.0–36.0 | 19.0–36.0 | |
| p-value* | 0.5905 | 0.2256 | |||||
| Height (cm) | |||||||
| Mean ± SD | 174.2 ± 5.4 | 174.6 ± 5.9 | 174.4 ± 5.6 | 175.1 ± 6.5 | 175.6 ± 5.3 | 175.3 ± 5.9 | |
| Range | 160.1–187.4 | 162.4–185.7 | 160.1–187.4 | 163.3–186.0 | 165.2–190.6 | 163.3–190.6 | |
| p-value* | 0.7824 | 0.7204 | |||||
| Weight (kg) | |||||||
| Mean ± SD | 70.6 ± 8.1 | 69.2 ± 7.7 | 69.9 ± 7.9 | 70.5 ± 8.7 | 72.7 ± 7.4 | 71.6 ± 8.0 | |
| Range | 55.1–92.9 | 55.7–85.0 | 55.1–92.9 | 55.4–87 | 57.8–87.1 | 55.4–87.1 | |
| p-value* | 0.4758 | 0.2968 | |||||
SD, standard deviation.
*p-value, two-sample t-test or Wilcoxon rank-sum test (continuous variables).
†R: Reference drug (fenofibric acid 135 mg capsule); T: Test drug (fenofibric acid 110 mg enteric-coated tablet).